Protagonist Therapeutics (PTGX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
The meeting was called to order by Matthew Gosling, EVP and Chief Legal and Business Officer, who introduced the board, executive officers, and external representatives in attendance.
The meeting was held virtually, allowing stockholders to submit questions and vote online.
The agenda included four proposals: election of directors, advisory vote on executive compensation, ratification of the auditor, and approval of the equity incentive plan.
Board and executive committee updates
Board members present included Dr. Dinesh Patel (President & CEO), Harold Selick, Bryan Giraudo, Sarah O'Dowd, William Waddill, and Lewis Williams.
Executive officers present were Dr. Patel, Asif Ali, and Arturo Molina.
Shareholder proposals
Four proposals were presented: election of two Class I directors, advisory approval of executive compensation, ratification of Ernst & Young as auditor, and adoption of the 2026 equity incentive plan.
Latest events from Protagonist Therapeutics
- Rusfertide achieved rapid, sustained Hct control and symptom relief in PV; phase 3 results due 2025.PTGX
Study Update9 Jul 2026 - Two first-in-class therapies near launch, backed by strong partnerships and financial strength.PTGX
TD Cowen 46th Annual Health Care Conference9 Jul 2026 - PN-477, a potent triple agonist, advances toward Phase 1 trials with dual oral and injectable options.PTGX
Status Update9 Jul 2026 - Rusfertide met all efficacy and safety endpoints in phase 3 PV trial; NDA filings planned for 2025.PTGX
Investor Update8 Jul 2026 - FDA approved the first oral IL-23R antagonist for moderate-to-severe plaque psoriasis.PTGX
FDA announcement30 Jun 2026 - Icotyde's strong launch and a robust pipeline drive growth, with Rusfertide approval expected soon.PTGX
Goldman Sachs 47th Annual Global Healthcare Conference 202610 Jun 2026 - Major partnerships, strong pipeline, and financial strength drive growth and shareholder returns.PTGX
Jefferies Global Healthcare Conference 20263 Jun 2026 - ICOTYDE and Rusfertide drive near-term growth, with a robust pipeline and strong financials.PTGX
Company presentation3 Jun 2026 - ICOTYDE approval and rusfertide milestones drove Q1 profitability and a strong cash position.PTGX
Q1 20265 May 2026